Sera Prognostics, INC 8-K filings

Sera Prognostics announced its second quarter 2026 financial results, detailing progress in commercial adoption, regulatory milestones, and scientific validation of its PreTRM test.

Sera Prognostics, Inc. announced the appointment of Mark Capone, an experienced healthcare executive, to its Board of Directors, effective July 1, 2026.

Sera Prognostics, Inc. successfully held its 2026 Annual Meeting of Stockholders, confirming the election of two directors and the ratification of its independent auditor.

Sera Prognostics announced that director Jeffrey T. Elliott will step down from the Board of Directors effective June 4, 2026.

Sera Prognostics announced its first quarter 2026 financial results, highlighting progress in commercialization efforts and an extended cash runway through 2029.

Sera Prognostics announced its fourth quarter and full year 2025 financial results, highlighting the landmark PRIME Study publication and extended cash runway through 2028.

Sera Prognostics, Inc. posted a new investor presentation highlighting the clinical validation and commercialization pathway for its PreTRM test, a predictor of spontaneous preterm birth risk.

A landmark study published in PREGNANCY demonstrates Sera Prognostics' PreTRM Test significantly reduces earliest preterm births and newborn complications when paired with targeted interventions.

Sera Prognostics announced the acceptance of its significant PRIME study findings for publication in a peer-reviewed medical journal.

Sera Prognostics reports Q3 2025 financial results, highlighting progress in payer engagement, key study publications, and strategic leadership appointments.

Sera Prognostics announces strong clinical validation and commercialization plans for its PreTRM test, aiming to redefine pregnancy care and reduce the burden of preterm birth.

Sera Prognostics announced its second quarter 2025 financial results, highlighting strategic commercialization efforts and upcoming pivotal study data publication.

Sera Prognostics, Inc. announced that its stockholders successfully re-elected two Class I directors and ratified Ernst & Young LLP as its independent auditor for the 2025 fiscal year at the Annual Meeting held on June 5, 2025.

Sera Prognostics names Lee Anderson as Chief Commercial Officer to spearhead commercial expansion and drive growth of the PreTRM Test.

Sera Prognostics announces its first quarter 2025 financial results, highlighting a revenue increase to $38,000 and ongoing engagement with payors for its PreTRM test.

Sera Prognostics announces positive results from its PRIME study, demonstrating significant reductions in neonatal morbidity and mortality, and secures $57.5 million in funding to expand commercial efforts and pursue FDA approval.

Sera Prognostics has priced a $50 million public offering of Class A common stock and pre-funded warrants to advance its commercial and research initiatives.

Sera Prognostics has terminated its At-the-Market offering of Class A Common Stock, but the sales agreement with TD Cowen remains in effect.

Sera Prognostics' PRIME study demonstrates a significant reduction in neonatal morbidity and hospital stays using the PreTRM test and targeted interventions.

Sera Prognostics highlights the clinical and economic benefits of its PreTRM test for predicting preterm birth in an investor presentation.

Sera Prognostics has released topline results from its PRIME study, indicating positive findings related to preterm birth risk assessment.

Sera Prognostics announced its third quarter 2024 financial results, highlighting progress in commercialization and research, while experiencing a slight revenue decrease compared to the same period last year.

Sera Prognostics announced a 21% reduction in net loss for Q2 2024, despite a significant decrease in revenue compared to the same period last year.

Sera Prognostics held its 2024 Annual Meeting of Stockholders, electing three directors and ratifying its independent auditor.

Sera Prognostics announced its first quarter 2024 financial results, highlighting a reduction in operating expenses and progress in commercial and research initiatives despite a revenue decrease due to adjustments.

Sera Prognostics reported positive results from its PRIME study, alongside its fourth quarter and full year 2023 financial results, highlighting progress in product development and commercial strategy.